RU2011133093A - Комбинированная терапия неопластических заболеваний - Google Patents

Комбинированная терапия неопластических заболеваний Download PDF

Info

Publication number
RU2011133093A
RU2011133093A RU2011133093/15A RU2011133093A RU2011133093A RU 2011133093 A RU2011133093 A RU 2011133093A RU 2011133093/15 A RU2011133093/15 A RU 2011133093/15A RU 2011133093 A RU2011133093 A RU 2011133093A RU 2011133093 A RU2011133093 A RU 2011133093A
Authority
RU
Russia
Prior art keywords
heteroacyl
heteroalkyl
acyl
independently
alkyl
Prior art date
Application number
RU2011133093/15A
Other languages
English (en)
Russian (ru)
Inventor
Денис ДРАЙГИН
Кэролайн Б ХО
Джошуа Р. БЛИЗЭТ
Кристофер Б. ПРОФФИТТ
Шон О'БРАЙН
Кенна ЭНДЕРС
Original Assignee
Сайлин Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайлин Фармасьютикалс, Инк. filed Critical Сайлин Фармасьютикалс, Инк.
Publication of RU2011133093A publication Critical patent/RU2011133093A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2011133093/15A 2009-01-08 2009-06-10 Комбинированная терапия неопластических заболеваний RU2011133093A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
US61/143,282 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
RU2011133093A true RU2011133093A (ru) 2013-02-20

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011133093/15A RU2011133093A (ru) 2009-01-08 2009-06-10 Комбинированная терапия неопластических заболеваний

Country Status (13)

Country Link
EP (1) EP2381942A1 (ja)
JP (1) JP2012514638A (ja)
KR (1) KR20110116153A (ja)
CN (1) CN102341107A (ja)
AU (1) AU2009336141A1 (ja)
BR (1) BRPI0924041A2 (ja)
CA (1) CA2749261A1 (ja)
IL (1) IL213969A0 (ja)
MX (1) MX2011007384A (ja)
RU (1) RU2011133093A (ja)
SG (1) SG172922A1 (ja)
WO (1) WO2010080170A1 (ja)
ZA (1) ZA201105755B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061765B1 (en) * 2006-09-01 2014-10-22 Senhwa Biosciences, Inc. Serine-threonine protein kinase and PARP modulators
CA2683804A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
EP2381942A1 (en) 2011-11-02
CN102341107A (zh) 2012-02-01
BRPI0924041A2 (pt) 2016-01-26
KR20110116153A (ko) 2011-10-25
AU2009336141A1 (en) 2011-08-11
IL213969A0 (en) 2011-08-31
SG172922A1 (en) 2011-08-29
WO2010080170A1 (en) 2010-07-15
JP2012514638A (ja) 2012-06-28
CA2749261A1 (en) 2010-07-15
ZA201105755B (en) 2012-04-25
MX2011007384A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
RU2012106518A (ru) Комбинированная терапия, включающая модуляторы ск2
AU2015317566B2 (en) Benzo-heterocyclic compounds and their applications
ES2620644T3 (es) Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
EP3529315A1 (en) Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
EP3672594A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
KR101230085B1 (ko) ７―(２,５-디히드로―４-이미다조［１,２-ａ］피리딘-３-일-２,５-디옥소-１ｈ-피롤-３-일)-９-플루오로-１,２,３,４-테트라히드로-２-(１-피페리디닐카르보닐)-피롤로［３,２,１-ｊｋ］［１,４］벤조디아제핀에 의한 암 화학요법의 강화
SK288524B6 (sk) 40-O-(2-hydroxyetyl)rapamycín na použitie ako jediná aktívna zložka pri liečení pevných nádorov mozgu iných ako lymfatická rakovina
Thompson et al. Animal models for studying the action of topoisomerase I targeted drugs
US8022047B2 (en) Combination anticancer agents
US20120219568A1 (en) Epidithiodioxopiprazines and uses thereof in treating cancer
CN105899196A (zh) (s)-3-(4-((4-(吗啉基甲基)苄基氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮的制剂
AU2020202332A1 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
US20130196938A1 (en) Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent
RU2011133093A (ru) Комбинированная терапия неопластических заболеваний
RU2411244C2 (ru) Производные камптотецина и их применение
JP2019506382A (ja) 癌及びウイルスを阻害するための化合物
WO2019207087A1 (en) Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor and an erk inhibitor and methods and use thereof
CA3121441C (en) Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug
BRPI0617730A2 (pt) agente para prevenir ou tratar cáncer do páncreas, cáncer de ovário ou cáncer hepático contendo nova pró-fármaco hidrossolúvel
Wahid et al. Camptothecin and its analogs antitumor activity by poisoning topoisomerase I, their structure activity relationship and clinical development perspective of analogs
CN103965175A (zh) 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用
RU2021114145A (ru) Комбинации для иммуномодуляции при лечении рака
US11696904B2 (en) Prodrug for therapeutic applications
JP6820567B2 (ja) 癌治療剤

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130605